School of Ageing and Chronic Disease, University Hospital Aintree, Lower Lane, Liverpool, UK.
Thorax. 2012 Aug;67(8):701-8. doi: 10.1136/thoraxjnl-2011-201458. Epub 2012 Jun 13.
Bronchodilator responsiveness is a potential phenotypic characteristic of chronic obstructive pulmonary disease (COPD). We studied whether change in lung function after a bronchodilator is abnormal in COPD, whether stable responder subgroups can be identified, and whether these subgroups experience different clinical outcomes.
1831 patients with COPD, 285 smoking (SC) and 228 non-smoking (NSC) controls from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Spirometric reversibility to 400 μg inhaled salbutamol was assessed on four occasions over 1 year.
Forced expiratory volume in 1 s (FEV(1)) increase after salbutamol was similar in SC (mean 0.14 litres (SD 0.15)) and COPD (0.12 litres (0.15)) and was significantly greater than NSC (0.08 litres (0.14)). Reversibility status varied with repeated testing in parallel with the day-to-day variation in pre-bronchodilator FEV(1), which was similar in control subjects and patients with COPD. Absolute FEV(1) change decreased by Global initiative for chronic Obstructive Lung Disease (GOLD) stage in patients with COPD (GOLD II, mean 0.16 litres (SD 0.17); III, 0.10 litres (0.13); IV, 0.05 litres (0.08) as did chances of being classified as reversible. CT-defined emphysema was weakly related to the absolute change in FEV(1) post salbutamol. Consistently reversible patients (n=227) did not differ in mortality, hospitalisation or exacerbation experience from irreversible patients when allowing for differences in baseline FEV(1).
Reversibility only assessed with salbutamol and defined by FEV(1) criteria. The COPD population was older than the control populations.
Post-salbutamol FEV(1) change is similar in patients with COPD and smoking controls but is influenced by baseline lung function and the presence of emphysema. Bronchodilator reversibility status varies temporally and does not distinguish clinically relevant outcomes, making it an unreliable phenotype.
支气管扩张剂反应性是慢性阻塞性肺疾病(COPD)的一种潜在表型特征。我们研究了 COPD 患者支气管扩张剂后肺功能的变化是否异常,是否可以确定稳定的应答亚组,以及这些亚组是否经历不同的临床结局。
1831 例 COPD 患者,285 例吸烟(SC)和 228 例非吸烟(NSC)对照,来自评估 COPD 纵向以确定预测替代终点(ECLIPSE)队列。在 1 年内的 4 次评估中,测定吸入 400 μg 沙丁胺醇后 1 秒用力呼气量(FEV1)的变化。
沙丁胺醇后 FEV1 的增加在 SC(平均 0.14 升(0.15 标准差))和 COPD(0.12 升(0.15))患者中相似,明显大于 NSC(0.08 升(0.14))。在与对照受试者和 COPD 患者相似的情况下,重复测试时,支气管扩张剂反应性状态与预支气管扩张剂 FEV1 的日常变化平行变化。在 COPD 患者中,绝对 FEV1 的变化随全球慢性阻塞性肺病倡议(GOLD)分期而减少(GOLD II,平均 0.16 升(0.17 标准差);III,0.10 升(0.13);IV,0.05 升(0.08)),被归类为可逆的可能性也减少。CT 定义的肺气肿与沙丁胺醇后 FEV1 的绝对变化呈弱相关。当考虑到基线 FEV1 的差异时,一致可逆转的患者(n=227)在死亡率、住院或恶化经验方面与不可逆转的患者没有差异。
仅使用沙丁胺醇评估可逆性,并根据 FEV1 标准定义。COPD 人群比对照人群年龄更大。
沙丁胺醇后 FEV1 的变化在 COPD 患者和吸烟对照者中相似,但受基线肺功能和肺气肿的影响。支气管扩张剂反应性状态随时间变化,不能区分有临床意义的结局,因此是一种不可靠的表型。